Development
Tarsus Pharmaceuticals, Inc.
TARS
$41.15
-$0.76-1.81%
NASDAQ
| 12/31/2023 | 09/30/2023 | 06/30/2023 | 03/31/2023 | 12/31/2022 | |
|---|---|---|---|---|---|
| Revenue | -32.42% | -11.04% | -28.14% | 15.09% | -54.73% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -32.42% | -11.04% | -28.14% | 15.09% | -54.73% |
| Cost of Revenue | 19.11% | 16.15% | 14.10% | 14.29% | -0.48% |
| Gross Profit | -93.99% | -33.71% | -45.86% | -12.91% | -234.16% |
| SG&A Expenses | 141.83% | 116.59% | 95.18% | 84.86% | 76.99% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 81.42% | 63.75% | 49.73% | 44.18% | 27.96% |
| Operating Income | -128.28% | -83.21% | -74.40% | -60.74% | -415.85% |
| Income Before Tax | -118.85% | -69.99% | -60.10% | -46.04% | -350.88% |
| Income Tax Expenses | -- | -100.00% | 98.25% | 98.05% | -107.27% |
| Earnings from Continuing Operations | -118.86% | -69.85% | -60.90% | -46.87% | -349.06% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -118.86% | -69.85% | -60.90% | -46.87% | -349.06% |
| EBIT | -128.28% | -83.21% | -74.40% | -60.74% | -415.85% |
| EBITDA | -128.06% | -82.98% | -74.34% | -60.93% | -426.69% |
| EPS Basic | -80.68% | -38.19% | -26.36% | -14.71% | -285.33% |
| Normalized Basic EPS | -80.03% | -41.05% | -29.16% | -18.84% | -338.56% |
| EPS Diluted | -80.37% | -37.80% | -26.01% | -13.70% | -255.50% |
| Normalized Diluted EPS | -80.03% | -41.05% | -29.16% | -17.55% | -298.24% |
| Average Basic Shares Outstanding | 18.00% | 20.03% | 23.81% | 26.47% | 19.71% |
| Average Diluted Shares Outstanding | 18.00% | 20.03% | 23.81% | 24.34% | 15.63% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |